Skip to main content
. Author manuscript; available in PMC: 2020 Jun 26.
Published in final edited form as: Cancer Discov. 2019 Aug 15;9(10):1372–1387. doi: 10.1158/2159-8290.CD-19-0582

Figure 3. Clinical efficacy of olaparib/temozolomide according to platinum sensitivity.

Figure 3.

(A) Best objective responses using RECIST 1.1 criteria are shown in waterfall plot. (B) Best confirmed responses. (C-E) Kaplan-Meier curves showing duration of response (C), progression-free survival (D) and overall survival (E), with medians (m) indicated at the top. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.